EP0809513A4 - Acide nucleique de poliovirus encapside recombine - Google Patents

Acide nucleique de poliovirus encapside recombine

Info

Publication number
EP0809513A4
EP0809513A4 EP96906392A EP96906392A EP0809513A4 EP 0809513 A4 EP0809513 A4 EP 0809513A4 EP 96906392 A EP96906392 A EP 96906392A EP 96906392 A EP96906392 A EP 96906392A EP 0809513 A4 EP0809513 A4 EP 0809513A4
Authority
EP
European Patent Office
Prior art keywords
encapside
poliovirus
recombinant
nucleic acid
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96906392A
Other languages
German (de)
English (en)
Other versions
EP0809513A1 (fr
Inventor
Casey D Morrow
Donna C Porter
David C Ansardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/389,459 external-priority patent/US5817512A/en
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of EP0809513A1 publication Critical patent/EP0809513A1/fr
Publication of EP0809513A4 publication Critical patent/EP0809513A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP96906392A 1993-07-01 1996-02-13 Acide nucleique de poliovirus encapside recombine Withdrawn EP0809513A4 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US8700993A 1993-07-01 1993-07-01
US08/389,459 US5817512A (en) 1993-07-01 1995-02-15 Encapsidated recombinant viral nucleic acid and methods of making and using same
US389459 1995-02-15
US08/589,446 US5614413A (en) 1993-07-01 1996-01-22 Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
PCT/US1996/001895 WO1996025173A1 (fr) 1993-07-01 1996-02-13 Acide nucleique de poliovirus encapside recombine
US08/987,867 US6063384A (en) 1993-07-01 1997-12-09 Encapsidated recombinant viral nucleic acid and methods of making and using same

Publications (2)

Publication Number Publication Date
EP0809513A1 EP0809513A1 (fr) 1997-12-03
EP0809513A4 true EP0809513A4 (fr) 1998-05-27

Family

ID=34468480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96906392A Withdrawn EP0809513A4 (fr) 1993-07-01 1996-02-13 Acide nucleique de poliovirus encapside recombine

Country Status (4)

Country Link
US (2) US5614413A (fr)
EP (1) EP0809513A4 (fr)
AU (1) AU4978496A (fr)
WO (1) WO1996025173A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051768A1 (en) * 1993-07-01 2002-05-02 Morrow Casey D. Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
DE19503082A1 (de) * 1995-02-01 1996-08-08 Univ Ludwigs Albert Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen
US5939262A (en) * 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US20070048860A1 (en) * 1997-10-10 2007-03-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Carcinoembryonic antigen (CEA) peptides
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2409190A1 (fr) * 2000-04-14 2001-10-25 The Uab Research Foundation Replicons de poliovirus codant des agents therapeutiques et utilisations de ceux-ci
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
CA2434546C (fr) 2001-01-12 2012-09-11 Chiron Corporation Induction de reponse immunitaire par une particule de replicon de virus chimere de l'encphalomyelite equine du venezuela-sindbis codant un antigene
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
US20030040498A1 (en) * 2001-03-14 2003-02-27 Ansardi David Calvert Oncolytic RNA replicons
IL157304A0 (en) * 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
EP1411770A4 (fr) * 2001-07-05 2006-05-10 Chiron Corp Polynucleotides codant des polypeptides de type c du vih antigeniques, polypeptides et leurs utilisations
EP2280074A3 (fr) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides codant pour des polypeptides antigeniques du vih de sous-type b et/ou de sous-type c, polypeptides et leurs utilisations
CA2458995C (fr) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides codant des polypeptides de type b du vih antigeniques, polypeptides et leurs utilisations
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US8617816B2 (en) * 2007-03-16 2013-12-31 454 Life Sciences, A Roche Company System and method for detection of HIV drug resistant variants
US8425922B2 (en) * 2009-01-05 2013-04-23 EpitoGenesis, Inc. Adjuvant compositions and methods of use
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
CA2789539A1 (fr) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection de virus de la stomatite vesiculeuse recombinant exprimant des proteines hiv-1 en neutralisant largement les anticorps
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
WO2014043518A1 (fr) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Protéine brachyury, vecteurs non levure, non poxvirus, codant pour la protéine brachyury, et leur utilisation
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (fr) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Trimères de glycoprotéines de l'enveloppe du vih-1 soluble
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP4137150A1 (fr) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Mutants de délétion de la protéine brachyury, vecteurs sans levure codant pour les mutants de délétion de la protéine brachyury, et leur utilisation
GB201700825D0 (en) * 2017-01-17 2017-03-01 Sec Dep For Health Poliovaccine
WO2022006491A1 (fr) * 2020-07-02 2022-01-06 The Regents Of The University Of California Entérovirus recombinants et utilisations associées
CN116377011B (zh) * 2023-02-28 2025-01-24 中国农业大学 非共价吸附法包裹蛋白质的dna病毒示踪剂及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125344A1 (fr) * 1993-07-01 1995-01-02 Casey D. Morrow Acide nucleique de poliovirus recombinant encapside et methodes de production et d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125344A1 (fr) * 1993-07-01 1995-01-02 Casey D. Morrow Acide nucleique de poliovirus recombinant encapside et methodes de production et d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MORROW C D ET AL: "Recombinant poliovirus expressing HIV proteins as mucosal vaccines.", KEYSTONE SYMPOSIUM ON MUCOSAL IMMUNITY: NEW STRATEGIES FOR PROTECTION AGAINST VIRAL AND BACTERIAL PATHOGENS, KEYSTONE, COLORADO, USA, JANUARY 16-23, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (19A). 1995. 238. ISSN: 0733-1959; ABSTR. J1-020, XP002058466 *
PORTER, DONNA C. ET AL: "Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection", J. VIROL. (1993), 67(7), 3712-19 CODEN: JOVIAM;ISSN: 0022-538X, XP000572057 *
See also references of WO9625173A1 *

Also Published As

Publication number Publication date
WO1996025173A1 (fr) 1996-08-22
EP0809513A1 (fr) 1997-12-03
US5614413A (en) 1997-03-25
US6063384A (en) 2000-05-16
AU4978496A (en) 1996-09-04

Similar Documents

Publication Publication Date Title
EP0809513A4 (fr) Acide nucleique de poliovirus encapside recombine
FI954329L (fi) Farmaseuttisina aineina käytettäviä nukleiinihappoja
FI944412L (fi) Proteiinin puhdistus
FI960253A7 (fi) Aerosolisoitujen proteiinien stabilointi
DE69401470D1 (de) Steuerknüppel
FI962247L (fi) Uudet apoptoosia muuntavat proteiinit, niitä koodaava DNA ja näiden käyttömenetelmät
DE69420284D1 (de) Percarbonsäuren
FI952574L (fi) Glykosyylitransferaasiaktiiviset proteiinit
DE69405329D1 (de) Reinigung von 2-Methylglutaro- oder Adiponitril
DE69518743D1 (de) Modifizierung von nukleotidanalogen
DK132892D0 (da) Proteiner
DE59402189D1 (de) 2-Keto-3-methyl-4-hydroxy-valeriansäure
DE59205477D1 (de) Stabilisatorgemisch
KR950702242A (ko) 사포린 함유 단백질의 재조합 생산방법(Recombinant production of saporin-containing proteins)
IS4629A (is) Samskeyttar veirukjarnsýrur
DE69417915D1 (de) Reinigung von uranhexafluorid
FI955559L (fi) Bentsotiofeenikarboksyylihappoamidi-S-oksideja
HUT77435A (hu) Aminosavat tartalmazó nukleotid monomer analógok
DE59003161D1 (de) STABILISIERUNG VON GLYKOSYLIERTEM t-PA.
NO961783D0 (no) 5-arylisoxazol-4-yl-substituerte 2-aminokarboksylsyreforbindelser
FI944997A7 (fi) Parannettu rekombinantti-proteiinien tuotanto
DE69520374D1 (de) Formen von Strukturelementen
DK75393D0 (da) Production of protein
NO944044L (no) Pall
FI946031L (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/43

A4 Supplementary search report drawn up and despatched

Effective date: 19980414

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20010427

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040301